{"id":"ag-013736","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AG-013736 inhibits VEGF receptors (VEGFR) and other receptor tyrosine kinases critical for tumor angiogenesis and vascular endothelial growth factor signaling. By blocking these pathways, the drug suppresses new blood vessel formation that tumors depend on for growth and metastasis. This multi-targeted approach aims to starve tumors of their blood supply while also directly inhibiting tumor cell proliferation.","oneSentence":"AG-013736 is a tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in angiogenesis and tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:12.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Axitinib","title":"Axitinib","extract":"Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types."},"indications":{"approved":[{"name":"Renal cell carcinoma"},{"name":"Other solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT07123090","phase":"PHASE2","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Stephanie Berg","startDate":"2025-11-24","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma","enrollment":25},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT05738694","phase":"PHASE3","title":"Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma","status":"RECRUITING","sponsor":"ZHOU FANGJIAN","startDate":"2023-04-19","conditions":"Renal Cell Carcinoma, Neoadjuvant","enrollment":298},{"nctId":"NCT07235085","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy","status":"RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2025-11-17","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":930},{"nctId":"NCT04693468","phase":"PHASE1","title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":111},{"nctId":"NCT07469683","phase":"PHASE2","title":"An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2026-03","conditions":"Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms","enrollment":78},{"nctId":"NCT06860386","phase":"PHASE2","title":"Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC","status":"SUSPENDED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-02-25","conditions":"Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":75},{"nctId":"NCT01409200","phase":"PHASE2","title":"Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03-26","conditions":"Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":73},{"nctId":"NCT03839498","phase":"PHASE2","title":"Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-01-22","conditions":"Pheochromocytoma, Paraganglioma","enrollment":6},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT05384496","phase":"PHASE2","title":"Axitinib and Nivolumab for the Treatment of Mucosal Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-17","conditions":"Mucosal Melanoma","enrollment":20},{"nctId":"NCT05805501","phase":"PHASE2","title":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-04-21","conditions":"Renal Cell Carcinoma","enrollment":199},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT02853331","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-09-16","conditions":"Renal Cell Carcinoma","enrollment":861},{"nctId":"NCT05553782","phase":"EARLY_PHASE1","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":"Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck","enrollment":30},{"nctId":"NCT07351266","phase":"","title":"Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-25","conditions":"Renal Cell Carcinoma (Kidney Cancer)","enrollment":10},{"nctId":"NCT06726421","phase":"PHASE3","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-18","conditions":"Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic","enrollment":252},{"nctId":"NCT05327686","phase":"PHASE2","title":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-02-01","conditions":"Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8","enrollment":240},{"nctId":"NCT04585815","phase":"PHASE1, PHASE2","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":34},{"nctId":"NCT03092856","phase":"PHASE2","title":"Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2017-07-19","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma","enrollment":62},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT07277972","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-15","conditions":"RCC, Renal Cell Cancer","enrollment":36},{"nctId":"NCT05363631","phase":"PHASE1, PHASE2","title":"Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2022-09-19","conditions":"Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic","enrollment":55},{"nctId":"NCT04996823","phase":"PHASE2","title":"Axitinib + Ipilimumab in Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-08-04","conditions":"Melanoma","enrollment":25},{"nctId":"NCT05579847","phase":"","title":"Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-10-19","conditions":"Renal Cell Carcinoma Stage IV","enrollment":20},{"nctId":"NCT03595124","phase":"PHASE2","title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-08","conditions":"Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8","enrollment":15},{"nctId":"NCT04941768","phase":"","title":"An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-08-09","conditions":"Carcinoma, Renal Cell","enrollment":105},{"nctId":"NCT04394975","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-08-20","conditions":"Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1","enrollment":421},{"nctId":"NCT05287464","phase":"","title":"International Multicentric Study ARON-1","status":"RECRUITING","sponsor":"Hospital of Macerata","startDate":"2022-03-10","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":1220},{"nctId":"NCT04370509","phase":"PHASE2","title":"Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2021-02-09","conditions":"Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":6},{"nctId":"NCT06962787","phase":"PHASE2","title":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-07-28","conditions":"Renal Cancer","enrollment":260},{"nctId":"NCT03172754","phase":"PHASE1, PHASE2","title":"Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2017-06-12","conditions":"Renal Cell Carcinoma","enrollment":98},{"nctId":"NCT03438708","phase":"PHASE2","title":"Prior Axitinib as a Determinant of Outcome of Renal Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2018-03-05","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":22},{"nctId":"NCT04640545","phase":"PHASE1","title":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma","status":"COMPLETED","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2020-05-12","conditions":"Advanced Melanoma","enrollment":79},{"nctId":"NCT07172386","phase":"PHASE2","title":"Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2025-07-31","conditions":"Renal Cell Carcinoma (RCC)","enrollment":40},{"nctId":"NCT04258956","phase":"PHASE2","title":"A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy","status":"COMPLETED","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2019-04-30","conditions":"Gastrointestinal Stromal Tumors","enrollment":58},{"nctId":"NCT04510597","phase":"PHASE3","title":"Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2021-03-08","conditions":"Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8","enrollment":364},{"nctId":"NCT06969001","phase":"PHASE1","title":"Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops","status":"COMPLETED","sponsor":"SCAI Therapeutics","startDate":"2025-05-29","conditions":"Wet Age Related Macular Degeneration","enrollment":48},{"nctId":"NCT07159191","phase":"PHASE2","title":"Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Advanced Renal Cell Carcinoma (aRCC)","enrollment":30},{"nctId":"NCT04458259","phase":"PHASE1","title":"Study of PF-07265807 in Participants With Metastatic Solid Tumors.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-09-24","conditions":"Neoplasm Metastasis","enrollment":88},{"nctId":"NCT05949632","phase":"PHASE1, PHASE2","title":"A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2024-04-16","conditions":"Advanced Solid Tumors","enrollment":5},{"nctId":"NCT02684006","phase":"PHASE3","title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-03-23","conditions":"Renal Cell Cancer","enrollment":886},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT04522323","phase":"PHASE1","title":"A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2020-08-05","conditions":"Advanced Renal Cell Carcinoma","enrollment":67},{"nctId":"NCT05891548","phase":"PHASE2","title":"Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2023-05-31","conditions":"Neovascular Age-related Macular Degeneration","enrollment":60},{"nctId":"NCT06161558","phase":"PHASE1","title":"Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-15","conditions":"Neoplasms","enrollment":""},{"nctId":"NCT02533258","phase":"","title":"Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12-02","conditions":"Renal Cell Carcinoma","enrollment":13},{"nctId":"NCT04493203","phase":"PHASE2","title":"Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma","status":"COMPLETED","sponsor":"Yana Najjar","startDate":"2020-12-18","conditions":"Advanced Melanoma, Unresectable Melanoma","enrollment":31},{"nctId":"NCT02912572","phase":"PHASE2","title":"Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-14","conditions":"Metastatic Endometrial Cancer","enrollment":106},{"nctId":"NCT06903312","phase":"PHASE4","title":"Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-15","conditions":"Renal Cell Cancer, Kidney Neoplasm, Immunotherapy","enrollment":409},{"nctId":"NCT05059522","phase":"PHASE3","title":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-09-29","conditions":"Advanced Malignancies, NSCLC, Ovarian Cancer","enrollment":68},{"nctId":"NCT06495918","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2024-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":825},{"nctId":"NCT03826589","phase":"NA","title":"Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Cervical Cancer","enrollment":23},{"nctId":"NCT04337970","phase":"PHASE1, PHASE2","title":"Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-04-06","conditions":"Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma","enrollment":23},{"nctId":"NCT02535533","phase":"PHASE1","title":"SLM + Axitinib for Clear Cell RCC","status":"COMPLETED","sponsor":"Mohammed Milhem","startDate":"2016-01","conditions":"Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)","enrollment":46},{"nctId":"NCT06223958","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2024-01-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":344},{"nctId":"NCT02597322","phase":"PHASE2","title":"Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-02","conditions":"cT2a N0NxM0 Renal Tumor","enrollment":21},{"nctId":"NCT05969496","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-04","conditions":"Renal Cancer, Kidney Cancer, Renal Cell Carcinoma","enrollment":17},{"nctId":"NCT05650164","phase":"","title":"Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2023-01-25","conditions":"Renal Cell Carcinoma","enrollment":171},{"nctId":"NCT06889649","phase":"PHASE2","title":"SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-01-01","conditions":"Radiation Therapy, Targeted Therapy, Immunotherapy","enrollment":30},{"nctId":"NCT05256472","phase":"PHASE2","title":"A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-07-06","conditions":"Renal Cell Carcinoma, First-line Treatment","enrollment":70},{"nctId":"NCT04659343","phase":"","title":"TDM for Optimized Outcome in Patients With mRCC.","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-11-01","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity","enrollment":200},{"nctId":"NCT03013946","phase":"PHASE3","title":"Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-01-18","conditions":"Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent","enrollment":121},{"nctId":"NCT05808608","phase":"PHASE1, PHASE2","title":"A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Hao Zeng","startDate":"2023-11-17","conditions":"Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma","enrollment":33},{"nctId":"NCT06364631","phase":"PHASE3","title":"CARE1 Pragmatic Clinical Trial","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-04-12","conditions":"Metastatic Kidney Cancer, Metastatic Kidney Carcinoma","enrollment":1250},{"nctId":"NCT04562441","phase":"PHASE2","title":"NPC - AXEL Study : Axitinib-Avelumab","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2021-05-06","conditions":"Recurrent or Metastatic NPC","enrollment":13},{"nctId":"NCT05097599","phase":"PHASE2","title":"StrataPATH™ (Precision Indications for Approved Therapies)","status":"TERMINATED","sponsor":"Strata Oncology","startDate":"2022-04-29","conditions":"Cancer, Advanced Solid Tumor","enrollment":11},{"nctId":"NCT05522231","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2022-10-27","conditions":"Advanced Renal Cell Carcinoma","enrollment":265},{"nctId":"NCT04682587","phase":"","title":"To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-02-24","conditions":"Renal Cell Carcinoma","enrollment":481},{"nctId":"NCT05941637","phase":"","title":"An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)","status":"NO_LONGER_AVAILABLE","sponsor":"Lynkcell Europe","startDate":"","conditions":"Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations","enrollment":""},{"nctId":"NCT05904730","phase":"PHASE1","title":"Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations","status":"COMPLETED","sponsor":"Lynkcell Europe","startDate":"2023-07-11","conditions":"Breast Cancer, Ovarian Cancer, Breast Neoplasms","enrollment":10},{"nctId":"NCT00828919","phase":"NA","title":"Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-03-07","conditions":"Solid Tumors","enrollment":52},{"nctId":"NCT06211114","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-02-09","conditions":"Collecting Duct Carcinoma","enrollment":30},{"nctId":"NCT01693822","phase":"PHASE2","title":"A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2012-10","conditions":"Clear-cell Metastatic Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT02639182","phase":"PHASE2","title":"A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-05-03","conditions":"Metastatic Renal Cell Carcinoma","enrollment":133},{"nctId":"NCT06690697","phase":"PHASE2","title":"Combination of Toripalimab and JS004 Therapy for ccRCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-01","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":80},{"nctId":"NCT03990571","phase":"PHASE2","title":"Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-22","conditions":"Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma","enrollment":40},{"nctId":"NCT02667886","phase":"PHASE1, PHASE2","title":"Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"X4 Pharmaceuticals","startDate":"2016-04-27","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":74},{"nctId":"NCT05363072","phase":"","title":"A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-05-02","conditions":"Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney","enrollment":1112},{"nctId":"NCT00700258","phase":"","title":"Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-13","conditions":"Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors","enrollment":1520},{"nctId":"NCT01263769","phase":"PHASE2","title":"Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-02","conditions":"Kidney Cancer","enrollment":39},{"nctId":"NCT06583369","phase":"NA","title":"The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-03-25","conditions":"Hand-Foot Syndrome","enrollment":220},{"nctId":"NCT04669366","phase":"","title":"Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-20","conditions":"Kidney Neoplasms","enrollment":1205},{"nctId":"NCT02636725","phase":"PHASE2","title":"Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Jonathan Trent, MD, PhD","startDate":"2016-04-19","conditions":"Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas","enrollment":33},{"nctId":"NCT06485908","phase":"PHASE1, PHASE2","title":"Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-10","conditions":"Medulloblastoma, Ependymoma","enrollment":40},{"nctId":"NCT02859012","phase":"PHASE2","title":"Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-09","conditions":"Recurrent ACC, metastaticACC, Unreaectable ACC","enrollment":60},{"nctId":"NCT06424626","phase":"PHASE1","title":"A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-05-21","conditions":"Melanoma, Mucosal Melanoma, Metastatic Melanoma","enrollment":60},{"nctId":"NCT05420220","phase":"PHASE2","title":"Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2022-07-15","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":54},{"nctId":"NCT04873895","phase":"PHASE1","title":"TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-01-24","conditions":"Colorectal Neoplasms Malignant","enrollment":5},{"nctId":"NCT04387500","phase":"PHASE2","title":"Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2021-07-01","conditions":"Carcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy","enrollment":41},{"nctId":"NCT03472560","phase":"PHASE2","title":"A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-02","conditions":"Non-Small Cell Lung Cancer, Urothelial Cancer","enrollment":61},{"nctId":"NCT02156895","phase":"","title":"Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-17","conditions":"Advanced Renal Cell Carcinoma","enrollment":111},{"nctId":"NCT05131646","phase":"","title":"Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2021-10-08","conditions":"Neovascular Age-related Macular Degeneration","enrollment":15},{"nctId":"NCT04540705","phase":"PHASE1","title":"A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-09-11","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT06279403","phase":"PHASE2","title":"Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-01","conditions":"Clear-cell Metastatic Renal Cell Carcinoma, Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy","enrollment":20},{"nctId":"NCT04989699","phase":"PHASE1","title":"Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2021-07-28","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":21},{"nctId":"NCT05096390","phase":"PHASE2","title":"Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-06-01","conditions":"Papillary Renal Cell Carcinoma Type 2","enrollment":72},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DEHYDRATION"},{"count":3,"reaction":"ENTERITIS"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"PNEUMONIA"},{"count":3,"reaction":"RESPIRATORY FAILURE"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"ACIDOSIS"},{"count":2,"reaction":"HYPERTENSION"},{"count":2,"reaction":"LIVER FUNCTION TEST ABNORMAL"},{"count":2,"reaction":"MUCOSAL INFLAMMATION"}],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Axitinib","axitinib"],"phase":"phase_3","status":"active","brandName":"AG-013736","genericName":"AG-013736","companyName":"University of Wisconsin, Madison","companyId":"university-of-wisconsin-madison","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AG-013736 is a tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in angiogenesis and tumor growth. Used for Renal cell carcinoma, Other solid tumors (in clinical development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}